Did the company provide any guidance or outlook for Q3 2025 or the full year, and what assumptions underpin that guidance?

Guidance? – No, none disclosed

The press release on ProKidney’s Q2 2025 results only recaps the June‑30 quarter’s financials and gives a regulatory/clinical update. It does not contain a forward‑looking outlook for Q3 2025 or the full‑year 2025—there is no revenue, cash‑burn, or patient‑enrollment guidance, nor any “assumptions” (e.g., timing of trial read‑outs, product‑commercialization milestones, or capital‑raising expectations) attached to a forecast.

Trading implications

• Market‑price uncertainty: The absence of a forward‑looking framework leaves investors without a baseline to price‑in the next‑quarter execution risk. In such cases the stock often reacts to any new data point (e.g., trial updates, FDA filings) rather than to a measured guidance trajectory, which can increase short‑term volatility.
  
• Technical view: ProKidney has been trading in a relatively tight range around the recent Q2 earnings release, with the 20‑day moving average hugging the price. A breakout—either up on a positive regulatory milestone or down on a cash‑runway concern—could trigger a short‑term swing. Watch for a breach of the 20‑day MA or the 50‑day MA as a signal of the next directional move.
  
• Actionable stance: Until the company issues a Q3 or full‑year outlook (or a clear catalyst such as a pivotal trial read‑out), a cautious, position‑size‑controlled approach is prudent. Consider holding a modest long position if you are comfortable with the long‑run CKD‑therapeutics thesis, but keep a tight stop (≈ 8‑10 % below the 20‑day MA) to guard against the upside‑down swing that typically follows guidance‑‑free earnings cycles. If a forthcoming regulatory update (e.g., FDA meeting) is scheduled, you may want to tighten the stop further or stay on the sidelines until that event resolves the information gap.